7 minute read
May 5, 2023

Upcycling a γ-Secretase Inhibitor for a Potentially First- & Best-In-Class Treatment for Aggressive Desmoid Tumors.

nirogacestat

oral gamma secretase inhibitor Ph. III for DT/AF + Ph. II for OvGCTs single-digit nanomolar potency for Aβ reduction in vitro Press release, February 27, 2023 / NEJM, March 9, 2023 Pfizer / SpringWorks Therapeutics, Inc.

twitterlinkedinprintemail

MOTY Nominees

Molecule of the Year